SANA at a glance
Sana Biotechnology, Inc. (SANA, SEC CIK 1770121) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Sana Biotechnology, Inc. (SANA) shares worth $348.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $348.7M · +2 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes from latest 10-K indicated; principal risks remain carried forward
- Regulatory risk: FDA class-wide boxed warnings for CAR T therapies following T-cell malignancies
- Technology risk: novel PSC-derived and fusogen platforms lack FDA-approved therapeutic precedent
- Operational risk: portfolio prioritization suspended two allogeneic CAR T programs
- Financial risk: substantial doubt regarding ability to continue as a going concern and need for additional funding
AI summary of the SANA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure consists only of legal furnishing language; substantive information is in Exhibit 99.1
- Information not deemed “filed” under Exchange Act Section 18, limiting associated liability exposure
Item EX-99.1: Item EX-99.1
- SC451 IND filing and Phase 1/2 initiation targeted for 2026, creating near-term clinical catalysts in type 1 diabetes
- UP421 demonstrated hypoimmune islet-cell survival and function through 14 months without immunosuppression
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the detailed results
Item EX-99.1: Item EX-99.1
- Q2 net loss improved to $63.6M, or $0.22 per share, from $93.8M, benefiting from no 2025 impairment charge
- Cash, equivalents, and marketable securities reached $160.5M, supported by $93.3M financing proceeds and providing runway into mid-2027
Item 5.07: Submission of Matters to a Vote of Security Holders
- All three Class II nominees elected for three-year terms ending at the 2029 annual meeting
- Hans E. Bishop received 117,452,573 votes for and 57,148,432 withheld, indicating comparatively weaker support
AI summaries of SANA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SANA
Don't miss the next SANA filing
- Alerts as it files. A push when SANA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SANA, by share count.
- Ask anything. An AI agent that reads every SANA filing and answers with sources.
SANA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bishop Hans Edgar | A | Oct 5, 2026 | 8,680 | - |
| PATEL DHAVALKUMAR DHIRAJLAL | F | Aug 27, 2026 | 41,158 | $4.11 |
| PATEL DHAVALKUMAR DHIRAJLAL | M | Aug 26, 2026 | 125,000 | - |
| PATEL DHAVALKUMAR DHIRAJLAL | M | Aug 26, 2026 | 125,000 | - |
| Bishop Hans Edgar | A | Jul 6, 2026 | 6,297 | - |
| Rosiello Robert L. | A | Jun 4, 2026 | 90,000 | - |
| REICIN ALISE | A | Jun 4, 2026 | 90,000 | - |
| Yang Patrick Y | A | Jun 4, 2026 | 90,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$293.1M | -$272.7M | -$250.3M |
| Net Income | -$283.3M | -$266.8M | -$244.2M |
| Balance Sheet | |||
| Total Assets | $565.3M | $501.0M | $416.9M |
| Equity | $287.5M | $250.5M | $160.9M |
| ROE | -98.5% | -106.5% | -151.8% |
| Per Share | |||
| EPS | - | $-1.16 | $-0.96 |
| Cash Flow | |||
| Operating CF | -$253.6M | -$223.2M | -$143.8M |
| CapEx | $20.0M | $33.4M | $938K |
Source: XBRL data in Sana Biotechnology, Inc. (SANA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SANA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $348.7M |
| Q1 2026 | 30 | $275.7M |
| Q4 2025 | 27 | $368.8M |
| Q3 2025 | 26 | $332.0M |
| Q2 2025 | 28 | $210.9M |
| Q1 2025 | 23 | $102.1M |
| Q4 2024 | 19 | $98.2M |
| Q3 2024 | 17 | $53.8M |
- Bank of America Corp+2.80M (+95%)
- BlackRock+2.43M (+17%)
- Vanguard Capital Management LLC+940.7K (+13%)
- State Street Corp+665.0K (+6%)
- Citigroup+212.1K (+351%)
- Millennium Management−937.5K (-59%)
- Goldman Sachs Group−813.2K (-26%)
- Two Sigma Investments−559.7K (-47%)
- Citadel Advisors LLC−407.9K (-72%)
- Morgan Stanley−320.2K (-22%)
- Ameriprise Financial+120.3K
- Allstate+19.6K
- Principal Financial Group+14.0K
- Fifth Third Bancorp+5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SANA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| SC 13G | May 21, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Apr 8, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SANA SEC filings: frequently asked questions
Which institutions hold SANA stock?
As of June 30, 2026, the largest Sana Biotechnology, Inc. (SANA) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($130.6 million), BlackRock ($58.2 million), State Street Corp ($39.1 million), Vanguard Capital Management LLC ($29.2 million), Bank of America Corp ($20.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did SANA report in its latest 8-K?
Sana Biotechnology, Inc. (SANA) filed an 8-K on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure). Reg FD disclosure consists only of legal furnishing language; substantive information is in Exhibit 99.1.
What are the latest SANA SEC filings?
Sana Biotechnology, Inc. (SANA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on October 6, 2026.
What is SANA's SEC CIK number?
Sana Biotechnology, Inc. (SANA)'s SEC Central Index Key (CIK) is 1770121. EDGAR lists every SANA filing under that number.
Ask anything about SANA
The research agent reads SANA's filings, financials, insider trades and 13F holders, then answers with sources.